این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
شنبه 22 آذر 1404
Journal of Pharmaceutical Care
، جلد ۱۲، شماره ۴، صفحات ۲۰۴-۲۱۲
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
Crocin Monotherapy in Non-Central Diabetic Macular Edema
چکیده انگلیسی مقاله
Background: Crocin can be utilized as an anti-inflammatory component of Saffron in diabetic macular edema (DME), which is known as the most common cause of vision loss in patients with diabetes mellitus (DM). Although anti-vascular endothelial growth factor (VEGF) agents are common in non-center involving DME (NCI-DME), there is no consensus on NCI-DME treatment. Methods: This before-after study was performed from October 2019 to August 2021. Twenty-six eyes of 16 patients with type 2 DM in Baghayipoor Clinic in Yazd, were treated with 15 mg crocin per day for 90 days. Patients had at least one eye with non-proliferative DR (NPDR) and NCI-DME along with no adherence to intravitreal injection or a contraindication of intravitreal injection. Central subfield thickness (CST), visual acuity, fasting blood sugar (FBS), and HbA1c were assessed once before and once after the study (day 90). Results: After 90 days of therapy, the mean CST significantly decreased to 2.8 μm (P-value=0.030), four patients had increased CST and 1 patient had a significantly decreased CST (≥25μm). The mean Logarithmic Minimum angle of resolution increased during the study. The Mean (±SD) FBS showed a significant improvement during the study from 174.7 (±60.41) at baseline up to 161.8 (±47.7) at day 90 (P-value = 0.012). HbA1c had no significant reduction. Nausea/vomiting and insomnia were among the reported adverse effects. Nevertheless, no one withdrew from the study because of the adverse effects. Conclusion: This study suggests Crocin’s positive impact on NCI-DME. It may also improve the glycemic profile of diabetic patients; however, more high-quality randomized clinical trials with larger sample sizes and longer durations are needed for validation.
کلیدواژههای انگلیسی مقاله
نویسندگان مقاله
| Mojtaba Mojtahedzadeh
1. Department of Clinical Pharmacy, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
| Masoud Reza Manaviat
2. Geriatric ophthalmology research center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
| Seyed Reza Mirjalili
Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
| Adeleh Sahebnasagh
4. Department of Internal Medicine, Clinical Research Center, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
| Mohammad Khan Ardani
Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
| Farahnaz Hoseinzadeh
Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
| Fatemeh Saghafi
6. Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
نشانی اینترنتی
https://jpc.tums.ac.ir/index.php/jpc/article/view/772
فایل مقاله
فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات